Eikon Therapeutics (EIKN) stock: insider trades, news & valuation
Health Care · Strong buyingShare price and insider trades
Eikon Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 6 insiders bought $52.2M and 0 sold $0 of EIKN stock on the open market, including a cluster buy that began Feb 4, 2026.
Get emailed when insiders cluster-buy stocks like EIKN
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
EIKN insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $1.0M | 1 | — | 0 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | $51.1M | 9 | — | 0 |
Valuation, profit and volume
Pick score 54/100Summary
Over the past 12 months, 6 Eikon Therapeutics, Inc. insiders reported open-market purchases totaling $52.2M, while 0 insiders reported sales totaling $0. The most recent cluster buy began on Feb 4, 2026, when 5 insiders bought a combined $51.1M. Among insiders with enough purchase history to measure, Tim Kutzkey (10% Owner) has the highest Insider Score at 100.
EIKN stock news and SEC filings
Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 8SEC | Tim Kutzkey10% Owner | Buy | 89,200new position | $11.56 | $1.0M | -35.4% | 100 |
| Feb 9SEC | Column Group Opportunity Iii, Lp10% Owner | Buy | 1,437,3234,312,139 held (+50%) | $18.00 | $25.9M | -58.5% | — |
| Feb 9SEC | Column Group Opportunity Iii, Lp10% Owner | Buy | 630,8811,319,164 held (+92%) | $18.00 | $11.4M | -58.5% | — |
| Feb 9SEC | Column Group Opportunity Iii, Lp10% Owner | Buy | 49,556148,840 held (+50%) | $18.00 | $892K | -58.5% | — |
| Feb 6SEC | Ventures V, L.p. Lux10% Owner | Buy | 138,888new position | $18.00 | $2.5M | -58.5% | — |
| Feb 6SEC | Ventures V, L.p. Lux10% Owner | Buy | 138,888new position | $18.00 | $2.5M | -58.5% | — |
| Feb 6SEC | Josh WolfeDirector | Buy | 138,888new position | $18.00 | $2.5M | -58.5% | — |
| Feb 6SEC | Josh WolfeDirector | Buy | 138,888new position | $18.00 | $2.5M | -58.5% | — |
| Feb 6SEC | Kenneth C FrazierDirector | Buy | 111,111new position | $18.00 | $2.0M | -58.5% | — |
| Feb 6SEC | Foresite Capital Opportunity Management V, Llc10% Owner | Buy | 55,5551,318,983 held (+4%) | $18.00 | $1000K | -58.5% | — |
Insiders at Eikon Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Column Group Opportunity Iii, Lp10% Owner | $38.1M | — | Feb 9, 2026 | — |
| Ventures V, L.p. Lux10% Owner | $5.0M | — | Feb 6, 2026 | — |
| Josh WolfeDirector | $5.0M | — | Feb 6, 2026 | — |
| Kenneth C FrazierDirector | $2.0M | — | Feb 6, 2026 | — |
| Tim Kutzkey10% Owner | $1.0M | — | Sep 8, 2026 | 100 |
| Foresite Capital Opportunity Management V, Llc10% Owner | $1000K | — | Feb 6, 2026 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
EIKN stock: common questions
Are Eikon Therapeutics, Inc. insiders buying EIKN stock?
In the past 12 months, 6 insiders reported open-market purchases of EIKN worth $52.2M. The latest was 10% Owner Tim Kutzkey bought $1.0M of EIKN at $11.56 — first open-market purchase in our records; opens a new position.
Are Eikon Therapeutics, Inc. insiders selling EIKN stock?
0 insiders reported sales worth $0 over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is EIKN's 52-week range?
Over the past year EIKN has traded between $7.33 and $16.26. It last closed at $7.47 on Oct 9, 2026.